BackgroundSince publication of the 2022 Drug Allergy Practice Parameters (DAPP) of the AAAAI and ACAAI it is unclear the extent to which the simplified and risk-stratified evaluation of cephalosporin allergy has been incorporated into allergy practice. ObjectiveWe aimed to assess current cephalosporin allergy testing practices using real case examples. MethodsAn 18-question REDCap survey was sent to the 136 members of the Adverse Reactions to Drugs, Biologics and Latex (ARDBL) Committee of the AAAAI between February-April 2023. ResultsForty-six (33.8%) ARDBL members completed the survey, following three email attempts. Most practicing in the United States (32, 69.6%), six (13.0%) in Canada, and the remaining from Europe and Asia. Almost half (47.7%) reported that the 2022 DAPP had increased their use of direct oral challenges. 91% would use cephalosporins in the setting of low-risk penicillin allergy history without testing. For low-risk cephalosporin reactions, 68% would perform a direct oral challenge (DOC) with the culprit drug. In severe immediate penicillin reactions, 23% would evaluate with penicillin-skin-testing before assessing cephalosporin allergy. For cephalosporin-related anaphylaxis, 48% would perform cephalosporin-based testing. For perioperative anaphylaxis with cefazolin, 57% would perform cephalosporin-based testing. For positive skin testing to cefazolin 79% chose to avoid the culprit drug with follow-up oral challenge to a structurally dissimilar cephalosporin. ConclusionIncreased uptake of DOC represents the initial impact of the 2022 DAPP. However, there is significant variation in testing practices of cephalosporin allergy even amongst drug allergy experts, reflecting a need for higher evidence base to guide consensus around testing higher risk reactions.